TBPH

Theravance Biopharma, Inc.

8.78 USD
+0.12 (+1.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Theravance Biopharma, Inc. stock is down -2.23% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 June’s closed higher than May. 100% of analysts rate it a buy.

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.